Scopolamine: An Experimental Tool

Badruddeen1*, Ghazanfer1, Juber Akhtar1 and Mahboobus Salam2

1Department of Pharmacology, Integral University, India
2CRIUM, India

Submission: April 10, 2018; Published: June 22, 2018

*Corresponding author: Badruddeen, Department of Pharmacology, Faculty of Pharmacy, Integral University, Kursi Road, Lucknow-226026, India, Tel: +91-9918196188; Email: badarmiracle@gmail.com

Abstract

The aim of this review is to highlight the chemistry, pharmacological effects and experimental values of scopolamine. It is a tropane alkaloid drug with muscarinic antagonist effects, also known as Hyoscine. It is on the World Health Organization’s List of Essential Medicines. Chemically it is 6,7b-epoxide of hyoscyamine, formed from hyoscyamine via 6b-hydroxyhyoscyamine. It is used to treat postoperative nausea and vomiting, gastrointestinal spasms, irritable bowel syndrome, etc. It is sometimes used as a premedication to surgery. It is experimentally used to evaluate nootropic and cholinergic drugs. Therefore it is further applied as a model for discovery and evaluation of new drugs and natural bioactive affecting cognitive function.

Introduction

Scopolamine is a tropane alkaloid drug with muscarinic antagonist effects, also known as Hyoscine. Scopolamine exerts its effects by acting as a competitive antagonist at muscarinic acetylcholine receptors; it is thus classified as an anti cholinergic (anti muscarinic) drug. Although it is generally mentioned as a nonspecific antagonist, there is secondary evidence for M1-receptor subtype specificity. It is on the World Health Organization’s List of Essential Medicines, the most important medications needed in a basic health system. Scopolamine is named after the plant genus Scopolia. The name “hyoscine” is derived from the scientific name of henbane (Hyoscyamus Niger).

Pharmacological Review of Scopolamine

A. Brown et al. [2] suggested that Scopolamine may impair temporal attention through a decrease in tonic alertness and that this decrease in alertness can be temporarily compensated by a phasic alerting response to a salient stimulus.

B. Dandan et al. [6] examined harmine effects on scopolamine induced memory impairment mice and APP/PS1 transgenic mice as one of the models for Alzheimer’s disease, using Morris Water Maze test.

C. Wohleb et al. [7] proposed that scopolamine reverses the inhibitory inter neurons in the PFC causing disinhibition of pyramidal neurons and amplified extracellular glutamate that stimulates the quick antidepressant reactions to these mediators.

D. Changrun et al. [8] showed that the treatment with scopolamine significantly increased the escape latency time, decreased the number of crossings, and shortened the time spent in the target quadrant, while poly galactic acid reversed this scopolamine induced effects.

E. Andrea et al. [9] suggested that the administration of scopolamine increases the activity marker Fos in the medial prefrontal cortex, including the infralimbic (IL) and prelimbic (PrL) subregions. Scopolamine micro infusions into the IL or the PrL formed substantial antidepressant reactions in the forced swim test, and neuronal silencing of IL or PrL obstructed the antidepressant properties of systemic scopolamine. The consequences also reveal that the systemic administration of a selective muscarinic acetylcholine receptor antagonist, VU0255035, created an antidepressant reaction and stimulated mechanistic target
of rapamycin complex 1 signaling in the PFC, related to the actions of scopolamine.

**Evaluation of Nootropic Effect**

A. Badruddeen et al. [10] examined the imaginable protective result of hydro-alcoholic extract of *Salvia haematodes* Wall root (HESH) on cognitive purposes in scopolamine-induced amnesia in adult Sprague Dawley rats. This study was observed acquisition SDL, retention SDL and locomotor activity significantly decreased while Ach E activity significantly increased in scopolamine-treated group as compared to normal control group. The acquisition SDL, retention SDL and locomotor activity were significantly increased while; Ach E activity was significantly decreased with all the doses of HESH as compared to scopolamine-treated group.

B. Memory impairment was induced in male Wistar rats by administration of scopolamine (1mg/kg intra peritoneally). Rats received oral doses of ramipril (0.225mg/kg) and losartan (2.25mg/kg) for a period of four weeks. Passive avoidance paradigm was used to assess learning and memory. Ramipril and losartan pre-treatment overturned the scopolamine-induced memory impairment, oxidative stress and hipoplastal degeneration which were marked by the results from behavioral, biochemical and histological studies [11].

C. Saline or scopolamine (16mg/kg, i.p.) was administered to male Wistar rats. The other three groups were pre-treated with *Nigella sativa* oil (NSO) (1ml/kg, p.o.), wheat germ oil (WGO) (170mg/kg, p.o.) and donepezil used as a reference drug (10mg/kg, p.o.) for 14 days before scopolamine injection. Cognitive and biochemical measurements were then assessed. NSO and WGO treated rat’s expressively overturned scopolamine-induced shortage of spatial and non-spatial functioning memory deficiency in the T maze change task and object recognition test, respectively [12].

D. Naringenin (50 and 100mg/kg) and donepezil (2.5mg/kg) were orally administered for 7 successive days. At the end of the treatment period, dementia was prompted by a single injection of scopolamine (20mg/kg; i.p). Scopolamine caused memory impairment that was combined by modifications in the projected neurotransmitters and acetyl cholinesterase action as well as enlarged brain oxidative stress. Pre-treatment with naringenin in both doses eased scopolamine-induced behavioural, neuro chemical and histological alterations in a manner similar to donepezil [13].

E. Morris water maze scale was engaged to test the amnesic influence of scopolamine and its reversal by *B. monniera*. Rota rod test was conducted to screen muscle coordination activity of mice. Scopolamine expressively reduced the acquisition and recovery of memory making both antero grade and retrograde amnesia [14].

**Evaluation of Cholinergic Activity**

i. In normal rats, Bifemelane Hydrochloride (30mg/kg, i.p.) slightly increased acetylcholine (ACh) content in the cerebral cortex. Scopolamine (1mg/kg, i.p.) decreased ACh level and pre-treatment of Bifemelane Hydrochloride attenuated the decrement of ACh level in the rats [15].

ii. The properties of cholinesterase inhibitors, cholinergic agonists, dopaminergic agonists and dopaminergic antagonists on the hyperactivity resulted by the muscarinic cholinergic antagonist scopolamine were assessed in mice. Scopolamine (0.3-10mg/kg) produced a dose-related increase in loco motor activity, with a peak effect at 3.0mg/kg [16].

iii. Atropine and scopolamine in low doses intensify basic activity, increase amphetamine stereotypy, and suppress catalepsy induced by injection of haloperidol. High doses lower body temperature, antagonize amphetamine stereotypy, and intensify the hypnotic action of chloral hydrate [17].

**References**


